The Lymphoma Hub was delighted to host an interview with Ulrich Jäger, Medical University of Vienna, Vienna, AT. We asked, What was new in aggressive non-Hodgkin lymphoma at this year's American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) virtual meetings?
This interview outlines three main fields of development:
- Chimeric antigen receptor (CAR) T-cell therapies
- CD19/CD22 bicistronic CARs
- Bispecific antibodies